Kaplan-Meier analysis of progression free survival of all patients with ATL who received alemtuzumab therapy from Phase II Study of Alemtuzumab (CAMPATH-1) in Patients with HTLV-1–Associated Adult T-cell Leukemia/lymphoma
Year: 2023
Type: other
Abstract: Kaplan-Meier analysis of progression free survival of all patients with ATL who received alemtuzumab therapy
Authors: Kamal Sharma, John E. Janik, Deirdre O'Mahony, Donn Stewart, Stefania Pittaluga, Maryalice Stetler-Stevenson, Elaine S. Jaffe, Mark Raffeld, Thomas A. Fleisher, Cathryn C. Lee, Seth M. Steinberg, Thomas A. Waldmann, John C. Morris
Language: English
Subfield: Immunology
Field: Immunology and Microbiology
Domain: Life Sciences
Open Access status: gold
OpenAlex ID: W4362403018